Floatz logo

Zoladex

PIK3CA Mutation

Relay Therapeutics, Inc.Phase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the PIK3CA Mutation cohort.

Asset / SponsorPhaseRating
Benzamide, N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)-
Relay Therapeutics, Inc.
Phase 3BB
FULVESTRANT
Relay Therapeutics, Inc.
Phase 3B
Capivasertib
Relay Therapeutics, Inc.
Phase 3B
Letrozole
Relay Therapeutics, Inc.
Phase 1CC
Rly-5836
Relay Therapeutics, Inc.
Phase 1CC

View all 16 →

Same molecule, other indications

Zoladex is also rated in:

HR+/HER2- Breast CancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →